Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of combretastatin A4 phosphate for subfoveal choroidal neovascularization in pathologic myopia
ISRCTN85551991Phase 2Completed
- Sponsor
- OXiGENE, Inc.
- Start
- Jan 2004
- Modality
- Small Molecules
01
Overview
Phase 2 trial of fosbretabulin in myopic maculopathy (MM), Subretinal neovascularization and degenerative myopia (2 arms), sponsored by OXiGENE, Inc. Primary endpoint: Best corrected ETDRS visual function. Started Jan 2004; status: completed.
02
Drugs
fosbretabulin
03
Conditions
myopic maculopathy (MM)Subretinal neovascularizationdegenerative myopia
Beyond the preview
Go deeper on ISRCTN85551991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85551991.